Garry E. Menzel, Ph.D., MBA


Dr. Garry Menzel is an operating partner at GHO Capital Partners LLP, the leading European specialist investor in global healthcare, where he supports a portfolio of companies. He was previously president and chief executive officer of TCR² Therapeutics, beginning in 2016, leading it from concept to clinical trial success prior to its merger in March 2023 with Adaptimmune where he continues to serve as a member of the board. Garry was a founding board member of Black Diamond Therapeutics, a clinical stage precision oncology company, and currently serves as chair of the audit committee. 

Prior to TCR2 Therapeutics, he was the chief financial officer at kidney dialysis and primary care physician company DaVita Healthcare and the chief operating officer at microRNA therapy company Regulus Therapeutics. Garry also had global leadership roles as a managing director running the biotechnology practices at Goldman Sachs and Credit Suisse. In addition, he was a consultant with Bain & Company. 

Dr. Menzel earned his Ph.D. from the University of Cambridge for studying the regulation of oncogenes in immune cells. He also has an M.B.A. from the Stanford Graduate School of Business and a Bachelor of Science degree, with honors, in Biochemistry from Imperial College.